Literature DB >> 10504276

Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue.

N G Lindquist1, B S Larsson, J Stjernschantz.   

Abstract

The melanocytes in the mammalian eye have been thought to produce melanin only during fetal development and in the very young individual. The recent discovery that latanoprost, a prostaglandin analogue used in the treatment of glaucoma, causes increased pigmentation of the iris in monkeys and in humans indicates that the iridial melanocytes can produce melanin in adult individuals. Using microautoradiography of HG-(3)H-methimazole, a false melanin precursor, we observed in an earlier study that there seems to be an ongoing melanogenesis in adult mice in the iridial melanocytes and in the iridial pigment epithelium. In the present study latanoprost (13,14-dihydro-17-phenyl-18,19,20-trinor-PGF(2alpha)-isoprop yl ester) was applied once daily to the right eye of seven cynomolgus monkeys; the left eye served as an untreated control. Two animals developed clear-cut increased pigmentation of the iris in the treated eye during the first three months of treatment. These animals were injected intravenously with G-(3)H-methimazole and were killed 24 hr after the injection. The eyes were removed, fixed in 4% formalin supplemented with 10% acetic acid and embedded in paraffin or Polybed 812. Sections from the eyes were used for microautoradiography and light microscopic examination. A high uptake of radioactivity was observed in a few melanocytes in the iris of the untreated eye. There were also a low uptake in the melanocytes in the stroma of the ciliary body and the choroid. No accumulation was observed in the iridial or retinal pigment epithelium. In the iris of the treated eye the only observed difference from the untreated eye was an increased amount of melanin in the iridial melanocytes and an increased uptake of radioactivity in a great number of these cells. Thus it seems likely that treatment with latanoprost in some individuals causes an increase of the low normal melanin synthesis in iridal melanocytes. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10504276     DOI: 10.1006/exer.1999.0718

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  7 in total

1.  Deletion in the OA1 gene in a family with congenital X linked nystagmus.

Authors:  M Preising; J P Op de Laak; B Lorenz
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

2.  Incidence of iris colour change in latanoprost treated eyes.

Authors:  M A Teus; E Arranz-Márquez; P Lucea-Suescun
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

3.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

4.  Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines.

Authors:  Masahiko Ayaki; Atsuo Iwasawa
Journal:  Clin Ophthalmol       Date:  2010-08-19

5.  A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.

Authors:  Daniel M Albert; Ronald E Gangnon; Hans E Grossniklaus; W Richard Green; Soesiawati Darjatmoko; Amol D Kulkarni
Journal:  Arch Ophthalmol       Date:  2008-05

6.  Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study.

Authors:  Fernando Pérez-Roca; Esther Rodrigo-Morales; Ingrid Garzón; Ana-Celeste Oliveira; Miguel-Ángel Martín-Piedra; Víctor Carriel; Ana-Isabel Ortiz-Pérez; Indalecio Sánchez-Montesinos; Antonio Campos; Miguel Alaminos
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

Review 7.  Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Authors:  Luciano Quaranta; Ivano Riva; Andreas Katsanos; Irene Floriani; Marco Centofanti; Anastasios G P Konstas
Journal:  Clin Ophthalmol       Date:  2015-04-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.